Mettler Toledo Stock (MTD)

XNYS Alert Compare

Health Care · Fundamental analysis

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Mettler Toledo is a maker of precision balances and lab instruments with roots in Switzerland. The company supplies lab balances, analytical instruments, industrial scales and inspection systems for production lines, for example in pharma, chemicals and food. As of Oct 11, 2026

Fact sheet (from the annual report) Laboratory instruments · Columbus, USA

The company makes precision instruments and offers related services. In the lab, its products range from balances and pipettes to titrators and pH meters and software for data analysis. For manufacturers there are inspection systems such as metal detectors, X-ray systems, checkweighers and cameras at the end of the production line. Supermarkets and other food retailers use scales and labeling solutions for fresh goods. Its customers include pharma and biotechnology, food manufacturers, chemicals, universities and food retail. As a rule, technically sophisticated instruments are sold through its own field sales force and simpler ones through indirect channels.

Automatically summarized from SEC annual report (10-K, filed Feb 6, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today −2.3%
  • 7 days −4.1%
  • 30 days −0.7%
  • 1 year +19.1%
Day range (last trading day)
−0.1%Price at 4% of the range+3.2%
52-week range
−38.6%Price at 82% of the range+8.4%
Distance from the all-time high
−7.7%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Fundamentals · Analysis method

Growth, margin, balance sheet, cash flow and dividend compared with the sector – with traffic lights and quality checks in the fundamental analysis. To the fundamental analysis

Fundamental analysis

Mettler Toledo · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 6, 2026.

For you first Dividend

The company pays no dividend.

For you first Valuation

The P/E is above its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
5 of 7
criteria with data met
Revenue per year (5 y)
+5.5%
EPS per year (5 y)
+11.0%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
5 of 6
criteria with data met
Net margin
21.6%
Cash flow ÷ profit
1.10x
backed from 1.0 · 3 years: 1.15x

For you first Trading

The overview of this stock shows the trend by timeframe.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 5 of 6 met · 2 without data

  • met: Gross margin above 40% 59.4%
  • no data: Operating margin above 15% not stated in the SEC filings
  • met: Net margin above 10% 21.6%
  • no data: Return on equity above 15% negative equity
  • met: Free cash flow margin above 10% 21.1%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • not met: Equity ratio above 30% −0.6%
Gross margin

59.4% Fiscal year 2025

Rank 68 of 100: higher than 68% of 370 peers (All). strong.

Rank 44 of 100: higher than 44% of 49 peers (Sector). medium.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Net margin

21.6% Fiscal year 2025

Rank 81 of 100: higher than 81% of 584 peers (All). strong.

Rank 79 of 100: higher than 79% of 63 peers (Sector). strong.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on assets

23.4% Fiscal year 2025 (total assets at year end)

Rank 96 of 100: higher than 96% of 594 peers (All). strong.

Rank 96 of 100: higher than 96% of 63 peers (Sector). strong.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

−0.6% Fiscal year 2025

Rank 6 of 100: higher than 6% of 595 peers (All). weak.

Rank 12 of 100: higher than 12% of 63 peers (Sector). weak.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

21.1% Fiscal year 2025

Rank 79 of 100: higher than 79% of 465 peers (All). strong.

Rank 73 of 100: higher than 73% of 61 peers (Sector). strong.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

848.6M USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 5 of 7 met

  • not met: Over 3 years, revenue grew by more than 5% per year +0.9%
  • met: Over 5 years, revenue grew by more than 5% per year +5.5%
  • met: Over 10 years, revenue grew by more than 5% per year +5.3%
  • not met: Over 3 years, EPS grew by more than 5% per year +3.1%
  • met: Over 5 years, EPS grew by more than 5% per year +11.0%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 4 of 5
  • met: Revenue rose in the last fiscal year +4.0%
Revenue growth 3 years

+0.9% per year

Rank 25 of 100: higher than 25% of 578 peers (All). weak.

Rank 27 of 100: higher than 27% of 62 peers (Sector). weak.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+5.5% per year

Rank 30 of 100: higher than 30% of 549 peers (All). weak.

Rank 31 of 100: higher than 31% of 60 peers (Sector). weak.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+5.3% per year

Rank 40 of 100: higher than 40% of 412 peers (All). medium.

Rank 21 of 100: higher than 21% of 50 peers (Sector). weak.

Median Health Care: +9.3%

Average growth per year over 10 fiscal years.

EPS growth 3 years

+3.1% per year

Rank 39 of 100: higher than 39% of 437 peers (All). medium.

Rank 45 of 100: higher than 45% of 54 peers (Sector). medium.

Median Health Care: +5.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+11.0% per year

Rank 48 of 100: higher than 48% of 399 peers (All). medium.

Rank 61 of 100: higher than 61% of 47 peers (Sector). medium.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+12.9% per year

Rank 65 of 100: higher than 65% of 375 peers (All). medium.

Rank 60 of 100: higher than 60% of 46 peers (Sector). medium.

Median Health Care: +9.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 0 of 1 met · 6 without data

  • not met: Pays a dividend no dividend per share reported for the last fiscal year
  • no data: Payout ratio at most 60% of earnings pays no dividend
  • no data: Dividend paid in each of the last 5 fiscal years pays no dividend
  • no data: Dividend per share never lowered in the last 5 fiscal years pays no dividend
  • no data: Dividend per share higher than 5 years ago pays no dividend
  • no data: Free cash flow per share covers the dividend pays no dividend
  • no data: Dividends paid over the last 5 years covered by free cash flow pays no dividend

Financial strength 4 of 6 met

  • met: Piotroski F-Score at least 7 of 9 8 of 9
  • not met: Long-term debt no higher than equity negative equity
  • met: Current assets cover current liabilities 1.14
  • not met: Positive equity −23.6M USD
  • met: In 5 years, share count up by at most 5% −14.6%
  • met: Free cash flow positive in the last fiscal year 848.6M USD
Piotroski F-Score

8 of 9 Fiscal year 2025

Rank 88 of 100: higher than 88% of 310 peers (All). strong.

Rank 85 of 100: higher than 85% of 47 peers (Sector). strong.

Median Health Care: 6.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

negative equity at fiscal year end

No rank: too few peers or not computed yet.

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.14 at fiscal year end

Rank 38 of 100: higher than 38% of 513 peers (All). medium.

Rank 23 of 100: higher than 23% of 63 peers (Sector). weak.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

−14.6% in 5 years

Rank 85 of 100: lower than 85% of 507 peers (All). strong.

Rank 84 of 100: lower than 84% of 59 peers (Sector). strong.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • not met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+5.5% per year), more slowly than the sector median.
  • Light green: Net income (total) grew over 5 years (+7.6% per year), at least as fast as the sector median; per share +11.0% per year.
  • Light green: Net margin 21.6%, above the sector median (13.9%).
  • Light red: Debt much higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 2.5B USD · Net income 384.4M USD · Net margin 15.3%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 2.7B USD · Net income 376.0M USD · Net margin 13.8%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 2.9B USD · Net income 512.6M USD · Net margin 17.5%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 3.0B USD · Net income 561.1M USD · Net margin 18.6%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 3.1B USD · Net income 602.7M USD · Net margin 19.5%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 3.7B USD · Net income 769.0M USD · Net margin 20.7%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 3.9B USD · Net income 872.5M USD · Net margin 22.3%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 3.8B USD · Net income 788.8M USD · Net margin 20.8%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 3.9B USD · Net income 863.1M USD · Net margin 22.3%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 4.0B USD · Net income 869.2M USD · Net margin 21.6%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 4.0B USD · Net income 869.2M USD · Net margin 21.6%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 +6.3% vs. the same quarter a year earlier; grown for 6 quarters in a row.

Revenue 12 months vs. prior 12
+6.5%
12 months: 4.2B USD · Fiscal year 2025: +4.0%
Net margin 12 months
22.2%
Fiscal year 2025: 21.6%
Free cash flow margin 12 months
20.7%
Fiscal year 2025: 21.1%
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Dec 31, 2025 4.0B USD + year to date to Sep 30, 2026 3.1B USD − same period a year earlier to Sep 30, 2025 2.9B USD = 4.2B USD
  • Net income: fiscal year to Dec 31, 2025 869.2M USD + year to date to Sep 30, 2026 648.3M USD − same period a year earlier to Sep 30, 2025 583.4M USD = 934.1M USD
  • Operating cash flow: fiscal year to Dec 31, 2025 955.8M USD + year to date to Sep 30, 2026 758.8M USD − same period a year earlier to Sep 30, 2025 730.2M USD = 984.4M USD
  • Capital expenditure: fiscal year to Dec 31, 2025 107.1M USD + year to date to Sep 30, 2026 72.3M USD − same period a year earlier to Sep 30, 2025 65.6M USD = 113.8M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 261.1B+6.3%246.0M22.5%
Apr–Jun 261.0B+4.5%232.9M22.7%
Jan–Mar 26947.1M+7.2%169.5M17.9%
Oct–Dec 25*1.1B+8.1%285.8M25.3%
Jul–Sep 251.0B+7.9%217.5M21.1%
Apr–Jun 25983.2M+3.9%202.3M20.6%
Jan–Mar 25883.7M−4.6%163.6M18.5%
Oct–Dec 24*1.0B+11.8%252.3M24.1%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Sep 30, 2026, filed on Nov 6, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Profit is backed by cash; interest is well covered.

Cash flow ÷ profit
1.10x
backed from 1.0 · 3 years: 1.15x
Interest coverage
16.3x
well covered from 5 · EBIT, derived · 3 years: 14.9x
Tax rate
17.1%
for information only · 3 years: 17.6%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 955.8M USD ÷ Net income 869.2M USD = 1.10x
  • EBIT, derived (profit before tax plus interest expense) 1.1B USD ÷ Interest expense 68.5M USD = 16.3x
  • Taxes 179.7M USD ÷ profit before tax 1.0B USD = 17.1%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20251.10x16.3x17.1%
20241.12x14.9x16.8%
20231.22x13.6x19.0%
20220.98x20.3x18.5%
20211.18x23.0x19.0%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years no loss year and one year with lower revenue.

Loss years
0 of 10
net income below zero
Years with lower revenue
1 of 10
revenue below the prior year
Net margin range
8.5 percentage points
from 13.8% to 22.3%
Net margin by fiscal year · ▾ revenue below the prior year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+4.0%21.6%
2024+2.2%22.3%
2023−3.4%20.8%
2022+5.4%22.3%
2021+20.5%20.7%
2020+2.5%19.5%
2019+2.5%18.6%
2018+7.7%17.5%
2017+8.6%13.8%
2016+4.7%15.3%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 59.4 USD gross profit and 21.6 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue4.0B USD100.0%
Gross profit2.4B USD59.4%
Cost of revenue1.6B USD40.6%
Net income869.2M USD21.6%
Research & development199.4M USD5.0%
Interest expense68.5M USD1.7%
Taxes179.7M USD4.5%
Remaining costs & other1.1B USD26.7%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The net margin rose in 5 years from 19.5% to 21.6%.

Gross marginNet margin
  1. Fiscal year 2016: Gross margin 57.2% · Net margin 15.3%
  2. Fiscal year 2017: Gross margin 57.7% · Net margin 13.8%
  3. Fiscal year 2018: Gross margin 57.4% · Net margin 17.5%
  4. Fiscal year 2019: Gross margin 57.9% · Net margin 18.6%
  5. Fiscal year 2020: Gross margin 58.4% · Net margin 19.5%
  6. Fiscal year 2021: Gross margin 58.4% · Net margin 20.7%
  7. Fiscal year 2022: Gross margin 58.9% · Net margin 22.3%
  8. Fiscal year 2023: Gross margin 59.2% · Net margin 20.8%
  9. Fiscal year 2024: Gross margin 60.1% · Net margin 22.3%
  10. Fiscal year 2025: Gross margin 59.4% · Net margin 21.6%

Returns

Return on equity rose in 5 years from 88.4% to 448.6%.

Return on equityReturn on assets Return on equity hidden where equity is below 5% of total assets.
  1. Fiscal year 2016: Return on equity 88.4% · Return on assets 17.7%
  2. Fiscal year 2017: Return on equity 68.7% · Return on assets 14.7%
  3. Fiscal year 2018: Return on equity 86.9% · Return on assets 19.6%
  4. Fiscal year 2019: Return on equity 133.3% · Return on assets 20.1%
  5. Fiscal year 2020: Return on equity 213.2% · Return on assets 21.4%
  6. Fiscal year 2021: Return on equity 448.6% · Return on assets 23.1%
  7. Fiscal year 2022: Return on equity not available · Return on assets 25.0%
  8. Fiscal year 2023: Return on equity not available · Return on assets 23.5%
  9. Fiscal year 2024: Return on equity not available · Return on assets 26.6%
  10. Fiscal year 2025: Return on equity not available · Return on assets 23.4%

Equity and long-term debt

The equity ratio fell in 5 years from 10.0% to −0.6%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 434.9M USD · Long-term debt 875.1M USD
  2. Fiscal year 2017: Equity 547.3M USD · Long-term debt 960.2M USD
  3. Fiscal year 2018: Equity 590.1M USD · Long-term debt 985.0M USD
  4. Fiscal year 2019: Equity 420.8M USD · Long-term debt 1.2B USD
  5. Fiscal year 2020: Equity 282.7M USD · Long-term debt 1.3B USD
  6. Fiscal year 2021: Equity 171.4M USD · Long-term debt 1.6B USD
  7. Fiscal year 2022: Equity 24.8M USD · Long-term debt 1.9B USD
  8. Fiscal year 2023: Equity −149.9M USD · Long-term debt 1.9B USD
  9. Fiscal year 2024: Equity −126.9M USD · Long-term debt 1.8B USD
  10. Fiscal year 2025: Equity −23.6M USD · Long-term debt 2.1B USD

Liquidity (current ratio)

The current ratio fell in 5 years from 1.26 to 1.14.

Current ratio
  1. Fiscal year 2016: Current ratio 1.53
  2. Fiscal year 2017: Current ratio 1.46
  3. Fiscal year 2018: Current ratio 1.42
  4. Fiscal year 2019: Current ratio 1.47
  5. Fiscal year 2020: Current ratio 1.26
  6. Fiscal year 2021: Current ratio 1.11
  7. Fiscal year 2022: Current ratio 1.20
  8. Fiscal year 2023: Current ratio 1.04
  9. Fiscal year 2024: Current ratio 1.02
  10. Fiscal year 2025: Current ratio 1.14

Cash flow

Free cash flow rose in 5 years from 632.2M USD to 848.6M USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 443.1M USD · Capital expenditure 124.0M USD · Free cash flow 319.1M USD
  2. Fiscal year 2017: Operating cash flow 516.3M USD · Capital expenditure 127.4M USD · Free cash flow 388.9M USD
  3. Fiscal year 2018: Operating cash flow 565.0M USD · Capital expenditure 142.7M USD · Free cash flow 422.3M USD
  4. Fiscal year 2019: Operating cash flow 603.5M USD · Capital expenditure 97.3M USD · Free cash flow 506.1M USD
  5. Fiscal year 2020: Operating cash flow 724.7M USD · Capital expenditure 92.5M USD · Free cash flow 632.2M USD
  6. Fiscal year 2021: Operating cash flow 908.8M USD · Capital expenditure 107.6M USD · Free cash flow 801.2M USD
  7. Fiscal year 2022: Operating cash flow 859.1M USD · Capital expenditure 121.2M USD · Free cash flow 737.8M USD
  8. Fiscal year 2023: Operating cash flow 965.9M USD · Capital expenditure 105.3M USD · Free cash flow 860.6M USD
  9. Fiscal year 2024: Operating cash flow 968.3M USD · Capital expenditure 103.9M USD · Free cash flow 864.4M USD
  10. Fiscal year 2025: Operating cash flow 955.8M USD · Capital expenditure 107.1M USD · Free cash flow 848.6M USD

Share count

The share count fell in 5 years by 14.6% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 27.0M
  2. Fiscal year 2017: Diluted share count 26.4M
  3. Fiscal year 2018: Diluted share count 25.8M
  4. Fiscal year 2019: Diluted share count 25.0M
  5. Fiscal year 2020: Diluted share count 24.2M
  6. Fiscal year 2021: Diluted share count 23.5M
  7. Fiscal year 2022: Diluted share count 22.7M
  8. Fiscal year 2023: Diluted share count 22.0M
  9. Fiscal year 2024: Diluted share count 21.3M
  10. Fiscal year 2025: Diluted share count 20.7M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Revenue

Revenue rose in 5 years from 3.1B USD to 4.0B USD.

MTD in USD
  1. Fiscal year 2016: MTD 2.5B USD
  2. Fiscal year 2017: MTD 2.7B USD
  3. Fiscal year 2018: MTD 2.9B USD
  4. Fiscal year 2019: MTD 3.0B USD
  5. Fiscal year 2020: MTD 3.1B USD
  6. Fiscal year 2021: MTD 3.7B USD
  7. Fiscal year 2022: MTD 3.9B USD
  8. Fiscal year 2023: MTD 3.8B USD
  9. Fiscal year 2024: MTD 3.9B USD
  10. Fiscal year 2025: MTD 4.0B USD

Earnings per share

Earnings per share rose in 5 years from 24.91 USD to 42.05 USD.

MTD USD per share
  1. Fiscal year 2016: MTD 14.22 USD
  2. Fiscal year 2017: MTD 14.24 USD
  3. Fiscal year 2018: MTD 19.88 USD
  4. Fiscal year 2019: MTD 22.47 USD
  5. Fiscal year 2020: MTD 24.91 USD
  6. Fiscal year 2021: MTD 32.78 USD
  7. Fiscal year 2022: MTD 38.41 USD
  8. Fiscal year 2023: MTD 35.90 USD
  9. Fiscal year 2024: MTD 40.48 USD
  10. Fiscal year 2025: MTD 42.05 USD

Share count

The share count fell in 5 years by 14.6% (mostly through share repurchases).

MTD
  1. Fiscal year 2016: MTD 27.0M
  2. Fiscal year 2017: MTD 26.4M
  3. Fiscal year 2018: MTD 25.8M
  4. Fiscal year 2019: MTD 25.0M
  5. Fiscal year 2020: MTD 24.2M
  6. Fiscal year 2021: MTD 23.5M
  7. Fiscal year 2022: MTD 22.7M
  8. Fiscal year 2023: MTD 22.0M
  9. Fiscal year 2024: MTD 21.3M
  10. Fiscal year 2025: MTD 20.7M

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The company pays no dividend.

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

The P/E is above its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
none pays no dividend
To shareholders (5 years)
4.6B USD 100% through repurchases
Share count over 5 years
−14.6% fewer shares – each share is a larger stake

What goes back to shareholders

Over 5 years, 4.6B USD went back to shareholders, 100% of it through share repurchases. That is 113% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid not available · Share repurchases 500.0M USD · New shares issued (including employee plans) not available · Free cash flow 319.1M USD
  2. Fiscal year 2017: Dividends paid not available · Share repurchases 400.0M USD · New shares issued (including employee plans) not available · Free cash flow 388.9M USD
  3. Fiscal year 2018: Dividends paid not available · Share repurchases 475.0M USD · New shares issued (including employee plans) not available · Free cash flow 422.3M USD
  4. Fiscal year 2019: Dividends paid not available · Share repurchases 775.0M USD · New shares issued (including employee plans) not available · Free cash flow 506.1M USD
  5. Fiscal year 2020: Dividends paid not available · Share repurchases 775.0M USD · New shares issued (including employee plans) not available · Free cash flow 632.2M USD
  6. Fiscal year 2021: Dividends paid not available · Share repurchases 1,000.0M USD · New shares issued (including employee plans) not available · Free cash flow 801.2M USD
  7. Fiscal year 2022: Dividends paid not available · Share repurchases 1.1B USD · New shares issued (including employee plans) not available · Free cash flow 737.8M USD
  8. Fiscal year 2023: Dividends paid not available · Share repurchases 900.0M USD · New shares issued (including employee plans) not available · Free cash flow 860.6M USD
  9. Fiscal year 2024: Dividends paid not available · Share repurchases 850.0M USD · New shares issued (including employee plans) not available · Free cash flow 864.4M USD
  10. Fiscal year 2025: Dividends paid not available · Share repurchases 800.0M USD · New shares issued (including employee plans) not available · Free cash flow 848.6M USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Mettler Toledo next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison MTD, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
MTD Mettler Toledo this stock 4.0B USD +5.5%59.4%–21.6%–−0.6%21.1%8/9
MRNA Moderna 1.9B USD +19.3%55.3%−158.1%−145.2%−32.6%70.1%−106.2%2/9
NVAX Novavax 1.1B USD +18.8%93.5%40.3%39.2%–−10.9%−22.3%5/9
Median of the sector 27 symbols 44.3B USD +8.4%67.2%18.0%14.6%14.3%38.4%15.8%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector MTD next to MRNA – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+5.5% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 5.5% per year on average, but more slowly than the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light green: above sector

+7.6% per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: +11.0% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 7.6% per year on average – at least as fast as the median company in the sector (+5.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

21.6% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue, 21.59 USD remained as profit – at least as much as the median company in the sector (13.9%). Five years ago the margin was 19.5%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light red: much higher

25.28 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 25.28 USD of financial debt – more than twice as much as the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light gray: none found

– Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
4.0B USD
Revenue vs. prior year
+4.0%
Net income (FY)
869.2M USD
Net income vs. prior year
+0.7%
EPS (FY)
42.05 USD
Superinvestors holding
4 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 6, 2026 · Balance sheet Sep 30, 2026 (filed Nov 6, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 4.0B869.2M 21.6% 42.05 – –
2024Dec 31, 2024 3.9B863.1M 22.3% 40.48 – –
2023Dec 31, 2023 3.8B788.8M 20.8% 35.90 – –
2022Dec 31, 2022 3.9B872.5M 22.3% 38.41 – –
2021Dec 31, 2021 3.7B769.0M 20.7% 32.78 – –
2020Dec 31, 2020 3.1B602.7M 19.5% 24.91 – –
2019Dec 31, 2019 3.0B561.1M 18.6% 22.47 – –
2018Dec 31, 2018 2.9B512.6M 17.5% 19.88 – –
2017Dec 31, 2017 2.7B376.0M 13.8% 14.24 – –
2016Dec 31, 2016 2.5B384.4M 15.3% 14.22 – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 1.1B246.0M 22.5% 12.29 – –
Q2/26Jun 30, 2026 1.0B232.9M 22.7% 11.55 – –
Q1/26Mar 31, 2026 947.1M169.5M 17.9% 8.33 – –
Q4/25*Dec 31, 2025 1.1B285.8M 25.3% – – –
Q3/25Sep 30, 2025 1.0B217.5M 21.1% 10.57 – –
Q2/25Jun 30, 2025 983.2M202.3M 20.6% 9.76 – –
Q1/25Mar 31, 2025 883.7M163.6M 18.5% 7.81 – –
Q4/24*Dec 31, 2024 1.0B252.3M 24.1% – – –
Q3/24Sep 30, 2024 954.5M211.5M 22.2% 9.96 – –
Q2/24Jun 30, 2024 946.8M221.8M 23.4% 10.37 – –
Q1/24Mar 31, 2024 925.9M177.5M 19.2% 8.24 – –
Q4/23*Dec 31, 2023 935.0M184.8M 19.8% – – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $2.1M2 people −$2.1M
6 months $00 people $6.8M4 people −$6.8M
12 months $00 people $20.0M5 people −$20.0M

Latest transactions

  • Nov 9, 2026 Keller Gerry Officer Open-market sale 25 shares · $43.5K · SEC
  • Nov 9, 2026 Keller Gerry Officer Open-market sale 410 shares · $710.8K · SEC
  • Aug 27, 2026 Kaltenbach Patrick Chief executive (CEO) Open-market sale 942 shares · $1.3M · SEC
  • Aug 5, 2026 Salice Thomas P Director Open-market sale 417 shares · $600.7K · SEC
  • Aug 3, 2026 Salice Thomas P Director Open-market sale 415 shares · $599.5K · SEC
  • Aug 3, 2026 Keller Gerry Officer Open-market sale 240 shares · $342.5K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Mettler Toledo?

All superinvestor portfolios

4 of 26 tracked superinvestors report a position.

Superinvestors with a position in Mettler Toledo, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Steve Cohen Point72 Asset Management 0.2% −26.6% reduced Q3 2026
Paul Tudor Jones Tudor Investment Corp < 0.1% −63.8% reduced Q3 2026
Bridgewater Associates < 0.1% +14.2% increased Q3 2026
Renaissance Technologies < 0.1% new Q3 2026

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on MTD yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: MTD

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close